WallStSmart

Medtronic PLC (MDT)vsMarvell Technology Group Ltd (MRVL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 333% more annual revenue ($35.48B vs $8.19B). MRVL leads profitability with a 32.6% profit margin vs 13.0%. MDT appears more attractively valued with a PEG of 1.45. MRVL earns a higher WallStSmart Score of 66/100 (B-).

MDT

Buy

58

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 6.7Quality: 5.0

MRVL

Strong Buy

66

out of 100

Grade: B-

Growth: 8.7Profit: 8.0Value: 3.7Quality: 7.0
Piotroski: 5/9Altman Z: 1.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTUndervalued (+26.5%)

Margin of Safety

+26.5%

Fair Value

$108.03

Current Price

$79.37

$28.66 discount

UndervaluedFair: $108.03Overvalued

Intrinsic value data unavailable for MRVL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$106.97B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

MRVL4 strengths · Avg: 9.3/10
Profit MarginProfitability
32.6%10/10

Keeps 33 of every $100 in revenue as profit

EPS GrowthGrowth
106.3%10/10

Earnings expanding 106.3% YoY

Market CapQuality
$143.68B9/10

Large-cap with strong market position

Revenue GrowthGrowth
22.1%8/10

Revenue surging 22.1% year-over-year

Areas to Watch

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

MRVL4 concerns · Avg: 3.5/10
PEG RatioValuation
1.934/10

Expensive relative to growth rate

Price/BookValuation
9.3x4/10

Trading at 9.3x book value

Altman Z-ScoreHealth
1.804/10

Grey zone — moderate risk

P/E RatioValuation
53.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.45 suggests the stock is reasonably priced for its growth.

Bull Case : MRVL

The strongest argument for MRVL centers on Profit Margin, EPS Growth, Market Cap. Profitability is solid with margins at 32.6% and operating margin at 18.7%. Revenue growth of 22.1% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Bear Case : MRVL

The primary concerns for MRVL are PEG Ratio, Price/Book, Altman Z-Score. A P/E of 53.5x leaves little room for execution misses.

Key Dynamics to Monitor

MDT profiles as a value stock while MRVL is a growth play — different risk/reward profiles.

MRVL carries more volatility with a beta of 1.82 — expect wider price swings.

MRVL is growing revenue faster at 22.1% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MRVL scores higher overall (66/100 vs 58/100), backed by strong 32.6% margins and 22.1% revenue growth. MDT offers better value entry with a 26.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Marvell Technology Group Ltd

TECHNOLOGY · SEMICONDUCTORS · USA

Marvell Technology, Inc. designs, develops, and sells analog, mixed-signal, digital signal processing, and integrated and independent integrated circuits. The company is headquartered in Wilmington, Delaware.

Visit Website →

Want to dig deeper into these stocks?